Document is current
Any future updates will be listed below
-
Authors
Subbiah, Vivek https://orcid.org/0000-0002-6064-6837
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA242845, R01CA273168, P30 CA016672)
- License Information
-
More Information
Article History
Received: 28 September 2022
Accepted: 11 November 2022
First Online: 16 January 2023
Competing interests
: None relevant to the manuscript. V.S. reports research funding/grant support for clinical trials from AbbVie, Agensys, Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicines, Boston Biomedical, Boston Pharmaceuticals, Celgene, D3 Bio, Dragonfly Therapeutics, Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Incyte, Inhibrx, Loxo Oncology, MedImmune, MultiVir, NanoCarrier, National Comprehensive Cancer Network, NCI-CTEP, Northwest Biotherapeutics, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Roche/Genentech, Takeda, Turning Point Therapeutics, UT MD Anderson Cancer Center and Vegenics; travel support from ASCO, ESMO, Helsinn Healthcare, Incyte, Novartis and PharmaMar; consultancy/advisory board participation for Helsinn Healthcare, Jazz Pharmaceuticals, Incyte, Loxo Oncology/Eli Lilly, MedImmune, Novartis, QED Therapeutics, Relay Therapeutics, Daiichi-Sankyo and R-Pharm US; and a relationship with Medscape.
